Innovation in Drug Discovery

Supercede Therapeutics develops novel therapeutics targeting biological pathways relevant to human disease. We apply bioinformatics (AI/ML) to make drug discovery more efficient, and focused clinical development strategies to reach patients in need faster. At Supercede, we are committed to integrity, excellence, and innovation in everything we do. We believe in putting patients first and working collaboratively to achieve our goals.

Supercede is assembling a pipeline of therapeutic compounds against clinically validated targets across renal, metabolic, neurological, and other disease indications. We will provide progress updates as preclinical and clinical milestones are achieved.

Supercede's lead program, STX-001, is a novel, oral small molecule inhibitor of the Activin receptor Type II (ACTRII) kinase, in preclinical development to treat obesity. Inhibition of the ACTRII signaling pathway has been shown in a Phase II clinical study to significantly reduce fat while stimulating an increase in lean body mass (muscle). Achieving significant fat loss together with preserving or increasing lean mass is a critical need for patients with obesity, whether as monotherapy or in combination with incretin (GLP-1) based treatments, and ACTRII inhibition is the only mechanism that has been clinically demonstrated to achieve this beneficial overall change in body composition.

Supercede is combining cutting edge bioinformatic technology across multiple stages of drug discovery, from target identification to lead compound generation. Through efficient program generation, we plan to focus our energy on answering the key questions that determine safety, biological activity, and clinical benefit of new drugs.

In June 2024, Supercede announced the closing of its Seed financing with a top tier venture firm investor. The financing will support preclinical studies on its lead program, STX-001, a novel oral small molecule ACTRII inhibitor to treat obesity. Having shown oral bioavailability and in vivo activity of its lead compounds in animal models, Supercede is excited about the promise of this program to provide a novel treatment for patients with obesity that promotes significant fat loss together with preservation or increase of lean muscle. Intellectual property covering Supercede's lead compounds was licensed from Fudan University (Shanghai, China) and East China Normal University (Shanghai, China), who were represented by bioSeedin for business development.